Drug intelligence / Profile preview

adenovirus type 7 vaccine live

Development stage: Approved
Lead developer: Teva Pharmaceutical Industries
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
Administration: Oral

Overview

Adenovirus type 7 vaccine live is a component of an oral vaccine used in combination with adenovirus type 4 vaccine to prevent febrile acute respiratory disease (ARD) caused by adenovirus types 4 and 7. The vaccine works by stimulating the body's immune system to produce antibodies against the virus. It is administered as enteric-coated tablets designed to pass intact through the stomach and release the live virus in the intestine. The vaccine contains live (not attenuated) virus and is approved for use in military populations 17 through 50 years of age.

Brand names: Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
Other names: Human adenovirus B serotype 7 strain 55142 antigen

Beyond the preview

Go deeper on adenovirus type 7 vaccine live.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adenovirus type 7 vaccine live.

Explore the full profile